Compile Data Set for Download or QSAR
Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 50010655
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50063910((R)-N*1*-((S)-2,2-Dimethyl-1-methylcarbamoyl-propy...)
Affinity DataIC50: 0.380nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097273((R)-N*1*-((S)-2,2-dimethyl-1-methylcarbamoyl-propy...)
Affinity DataIC50: 0.5nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097273((R)-N*1*-((S)-2,2-dimethyl-1-methylcarbamoyl-propy...)
Affinity DataIC50: 1nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097270((R)-2-(3-Biphenyl-4-yl-propyl)-N*1*-[(S)-2,2-dimet...)
Affinity DataIC50: 2.60nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097261((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 3.80nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097263((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 5.90nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097272((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 7.20nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097268((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...)
Affinity DataIC50: 8.80nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097267((R)-N*1*-[(S)-1-(benzhydryl-carbamoyl)-2,2-dimethy...)
Affinity DataIC50: 10nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097261((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 11nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097271((R)-2-[3-(2-chloro-biphenyl-4-yl)-propyl]-N*1*-[(S...)
Affinity DataIC50: 13nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097262((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 25nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097265((R)-N*1*-[(S)-2,2-dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 26nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097270((R)-2-(3-Biphenyl-4-yl-propyl)-N*1*-[(S)-2,2-dimet...)
Affinity DataIC50: 34nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097260((R)-N*1*-((S)-2,2-Dimethyl-1-methylcarbamoyl-propy...)
Affinity DataIC50: 40nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097252((R)-N'-((S)-3,3-dimethyl-1-oxo-1-((R)-1-phenylethy...)
Affinity DataIC50: 40nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097267((R)-N*1*-[(S)-1-(benzhydryl-carbamoyl)-2,2-dimethy...)
Affinity DataIC50: 41nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097239((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...)
Affinity DataIC50: 48nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50063910((R)-N*1*-((S)-2,2-Dimethyl-1-methylcarbamoyl-propy...)
Affinity DataIC50: 48nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097252((R)-N'-((S)-3,3-dimethyl-1-oxo-1-((R)-1-phenylethy...)
Affinity DataIC50: 61nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCollagenase 3(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097263((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 73nMAssay Description:Inhibition of Matrix metalloprotease-13More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097260((R)-N*1*-((S)-2,2-Dimethyl-1-methylcarbamoyl-propy...)
Affinity DataIC50: 86nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097262((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 100nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097266((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 110nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097259((R)-2-(3-Cyclohexyl-propyl)-N*1*-[(S)-2,2-dimethyl...)
Affinity DataIC50: 120nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097265((R)-N*1*-[(S)-2,2-dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 210nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097268((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...)
Affinity DataIC50: 310nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097272((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 335nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097239((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...)
Affinity DataIC50: 414nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097264((R)-N*1*-[(S)-2,2-dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 450nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetStromelysin-1(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097269((R)-N*1*-[(S)-2,2-dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 770nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMatrix metalloproteinase-9(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097263((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 840nMAssay Description:Inhibition of Matrix metalloprotease-9More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097259((R)-2-(3-Cyclohexyl-propyl)-N*1*-[(S)-2,2-dimethyl...)
Affinity DataIC50: 920nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097271((R)-2-[3-(2-chloro-biphenyl-4-yl)-propyl]-N*1*-[(S...)
Affinity DataIC50: 1.30E+3nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097266((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 1.70E+3nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097263((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 1.79E+3nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMatrix metalloproteinase-14(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097263((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibition of Matrix metalloprotease-14More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097264((R)-N*1*-[(S)-2,2-dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 6.80E+3nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetInterstitial collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097263((R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 5.10E+4nMAssay Description:Inhibition of Matrix metalloprotease-1More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target72 kDa type IV collagenase(Human)
Pfizer

Curated by ChEMBL
LigandPNGBDBM50097269((R)-N*1*-[(S)-2,2-dimethyl-1-((R)-1-phenyl-ethylca...)
Affinity DataIC50: 5.20E+4nMAssay Description:Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed